How Does HRT Induce Puberty in Children With 46,XY DSD?
At a Glance
In 46,XY DSD, estrogen or testosterone can gradually induce puberty when the gonads are absent or do not make enough hormones. Treatment usually progresses over two to three years, with monitoring for bone health, side effects, fertility concerns, and lifelong replacement needs.
In this answer
4 sections
If your child’s gonads were removed or do not produce enough hormones, they will go through puberty with the help of hormone replacement therapy (HRT). A pediatric endocrinologist will start them on a pubertal induction protocol, which involves giving very low, gradually increasing doses of either estrogen or testosterone [1][2]. By slowly increasing the hormone levels over two to three years, the medical team closely approximates typical pubertal timing, helping your child develop physically and emotionally [3][4].
Timing and Decision Making
There is no single “right” time to start puberty. While hormone therapy is often considered around ages 11 to 12, the exact timing is highly individualized [1][5]. It depends on your child’s specific 46,XY DSD diagnosis, their overall growth, and, most importantly, their affirmed gender identity and readiness. The decision should be a collaborative process involving you, your child, and a multidisciplinary team (a group of different specialists working together, such as endocrinologists, urologists, and psychologists) [6].
How Pubertal Induction Works
The goal of pubertal induction is not to rush development, but to guide the body through a gradual transition over 2 to 3 years before settling into a long-term maintenance dose. The specific hormones used will depend on your child’s gender identity and the physical changes they desire.
Estrogen-Based Puberty
If an estrogen-based puberty is desired, the endocrinologist will prescribe estrogen to promote feminizing changes like breast development. This is often given as a transdermal patch (placed on the skin) or an oral pill, starting at a very low dose [7][8]. Over several years, the dose is slowly increased [3].
If your child has a uterus, a second hormone called a progestogen is usually added 12 to 24 months after starting estrogen, or after their first instance of breakthrough bleeding (unexpected vaginal bleeding) [9][10]. The main purpose of the progestogen is to protect the uterine lining and create predictable bleeding [3]. Children without a uterus do not need a progestogen for this purpose and will not have menstrual bleeding.
Testosterone-Based Puberty
If a testosterone-based puberty is desired, your child will receive testosterone to promote masculinizing secondary sex characteristics (physical traits that develop during puberty, such as a deepening voice, facial hair, and increased muscle mass) [11][4]. Keep in mind that some changes, like voice deepening, are permanent.
Testosterone is most commonly given via injections or transdermal gels [2][12]. While oral testosterone exists, certain forms are rarely used in adolescents due to how they are processed by the liver. The dose starts very low and is increased step-by-step. Keep in mind that individual response to testosterone varies by diagnosis; for example, if the body’s androgen receptors do not respond fully to hormones, the virilizing effects will be milder [13].
Why A Gradual Approach?
Starting with a low dose and escalating slowly is crucial for your child’s health. This gradual approach provides several key benefits:
- Healthy Skeletal Development: Sex hormones are essential for building bone mass. A slow increase supports healthy bone mineralization and balances growth with the eventual fusion of the growth plates [4][14]. It does not guarantee a specific adult height, but it supports healthy skeletal development.
- Physical Development: A gradual escalation ensures that physical changes happen at a steady pace, allowing the body time to adjust [15].
- Psychological Adjustment: Going through puberty as a process rather than a sudden event allows the care team to respond to your child’s emotional needs, giving them time to adjust to their changing body [1].
Long-Term Care, Monitoring, and Safety
Pubertal induction is a 2- to 3-year process, but if your child’s gonads have been removed, they will require lifelong hormone replacement therapy at an adult maintenance dose to stay healthy [16]. Do not stop or change hormone doses without speaking to your care team.
During the induction process, the medical team will monitor several factors to ensure safety and progress:
- Physical changes: Tracking height, weight, blood pressure, and pubertal development [17].
- Bone health: Checking bone age (an X-ray of the hand that estimates skeletal maturity, not actual bone strength) [18]. If your child has been without hormones for a long time, a DXA scan may be used to measure actual bone density [18].
- Lab work: Monitoring hormone levels. For those on testosterone, tests will likely include checking red blood cell counts (hematocrit) and liver function, as testosterone can affect these [19].
Possible Side Effects: As with any natural or induced puberty, hormone shifts can cause side effects. Estrogen may cause breast tenderness, headaches, or mood changes. Testosterone can cause acne, mood shifts, and increased red blood cell counts. Speak to your doctor if side effects become unmanageable.
Fertility: It is important to know that while HRT induces physical changes, it does not restore gonadal function or fertility [20]. Depending on the diagnosis and anatomy, fertility preservation and reproductive counseling should be discussed with the medical team before starting HRT [21][6].
Because puberty can be complex to navigate, ongoing support from a DSD-informed mental health professional is an essential part of care, helping your child discuss their identity, body changes, and future goals [6][22].
Common questions in this guide
When is hormone replacement therapy usually started for puberty in 46,XY DSD?
How does pubertal induction work in 46,XY DSD?
How are estrogen and testosterone used for puberty in 46,XY DSD?
Does a child with a uterus need another hormone during estrogen therapy?
What monitoring is needed during hormone replacement therapy for puberty?
Can hormone replacement therapy restore fertility in 46,XY DSD?
What side effects can estrogen or testosterone therapy cause?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What hormone delivery method do you recommend for my child's specific goals, and what are the formulation-specific risks?
- 2.If my child has a uterus, at what point during the estrogen induction process would a progestogen be added?
- 3.How frequently will we need to visit the clinic for dose adjustments and blood tests once HRT begins?
- 4.When do we transition from the 2- to 3-year induction phase to a long-term adult maintenance dose?
- 5.Who should we contact if my child experiences unexpected side effects, such as sudden mood changes, severe acne, or unexpected bleeding?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (22)
- 1
Pubertal induction and transition to adult sex hormone replacement in patients with congenital pituitary or gonadal reproductive hormone deficiency: an Endo-ERN clinical practice guideline.
Nordenström A, Ahmed SF, van den Akker E, et al.
European journal of endocrinology 2022; (186(6)):G9-G49 doi:10.1530/EJE-22-0073.
PMID: 35353710 - 2
Evaluation of 451 Danish boys with delayed puberty: diagnostic use of a new puberty nomogram and effects of oral testosterone therapy.
Lawaetz JG, Hagen CP, Mieritz MG, et al.
The Journal of clinical endocrinology and metabolism 2015; (100(4)):1376-85 doi:10.1210/jc.2014-3631.
PMID: 25594861 - 3
Induction of puberty in hypogonadal forms of primary amenorrhoea: current evidence and future perspectives.
Profka E, Rodari G, Citterio V, et al.
Endocrine connections 2026; (15(4)).
PMID: 41921012 - 4
Growth, sexual and bone development in a boy with bilateral anorchia under testosterone treatment guided by the development of his monozygotic twin.
Vandewalle S, Van Caenegem E, Craen M, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2018; (31(3)):361-367 doi:10.1515/jpem-2017-0126.
PMID: 29353265 - 5
Estrogen Replacement in Turner Syndrome: Literature Review and Practical Considerations.
Klein KO, Rosenfield RL, Santen RJ, et al.
The Journal of clinical endocrinology and metabolism 2018; (103(5)):1790-1803 doi:10.1210/jc.2017-02183.
PMID: 29438552 - 6
Clinical Spectrum, Surgical Management, and Outcomes of NR5A1-Related 46,XY Differences of Sex Development: A Narrative Review.
Vicario S, Escolino M, Esposito G, et al.
Medicina (Kaunas, Lithuania) 2025; (61(11)) doi:10.3390/medicina61111965.
PMID: 41303802 - 7
Two Cases of 46,XY Differences of Sex Development Due to Gonadal Dysgenesis Associated With Novel NR5A1 Variants.
Gialouris JV, Cheong PL, Zekanovic S, et al.
JCEM case reports 2025; (3(10)):luaf187 doi:10.1210/jcemcr/luaf187.
PMID: 40860577 - 8
Late-Onset Puberty Induction by Transdermal Estrogen in Turner Syndrome Girls-A Longitudinal Study.
Gawlik AM, Hankus M, Szeliga K, et al.
Frontiers in endocrinology 2018; (9()):23 doi:10.3389/fendo.2018.00023.
PMID: 29472893 - 9
Timing and regimen of puberty induction in children with hypogonadism: a survey on the practice in Arab countries.
Hamza RT, Deeb A, Al Saffar H, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2020; (33(9)):1197-1202 doi:10.1515/jpem-2020-0157.
PMID: 32809957 - 10
Towards an individualized management of pubertal induction in girls with hypogonadism: insight into the best replacement outcomes from a large multicentre registry.
Rodari G, Federici S, Todisco T, et al.
European journal of endocrinology 2023; (188(6)):467-476 doi:10.1093/ejendo/lvad056.
PMID: 37232247 - 11
Testosterone Use in Adolescent Males: Current Practice and Unmet Needs.
Vogiatzi M, Tursi JP, Jaffe JS, et al.
Journal of the Endocrine Society 2021; (5(1)):bvaa161 doi:10.1210/jendso/bvaa161.
PMID: 33294762 - 12
Testosterone Therapy and Its Monitoring in Adolescent Boys with Hypogonadism: Results of an International Survey from the I-DSD Registry.
Stancampiano MR, Lucas-Herald AK, Bryce J, et al.
Sexual development : genetics, molecular biology, evolution, endocrinology, embryology, and pathology of sex determination and differentiation 2021; (15(4)):236-243 doi:10.1159/000516784.
PMID: 34350903 - 13
Close relationship, similar phenotype of GATA4 and NR5A1 mutations: gonadal dysgenesis and puberty development.
Abseyi SN, Şıklar Z, Özsu E, et al.
Journal of endocrinological investigation 2025; (48(12)):2933-2942 doi:10.1007/s40618-025-02684-4.
PMID: 41023526 - 14
Hypogonadism in Male Infants and Adolescents: New Androgen Formulations.
Chioma L, Cappa M
Hormone research in paediatrics 2023; (96(6)):581-589 doi:10.1159/000521455.
PMID: 34915486 - 15
Hypogonadism in adolescent girls: treatment and long-term effects.
Voutsadaki K, Matalliotakis M, Ladomenou F
Acta bio-medica : Atenei Parmensis 2022; (93(5)):e2022317 doi:10.23750/abm.v93i5.13719.
PMID: 36300209 - 16
A Risk of Gonadoblastoma in Familial Swyer Syndrome-A Case Report and Literature Review.
Rudnicka E, Jaroń A, Kruszewska J, et al.
Journal of clinical medicine 2024; (13(3)) doi:10.3390/jcm13030785.
PMID: 38337479 - 17
Sex Steroid Replacement Therapy in Female Hypogonadism from Childhood to Young Adulthood.
Norjavaara E, Ankarberg-Lindgren C, Kriström B
Endocrine development 2016; (29()):198-213 doi:10.1159/000438892.
PMID: 26680580 - 18
Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
Bhasin S, Brito JP, Cunningham GR, et al.
The Journal of clinical endocrinology and metabolism 2018; (103(5)):1715-1744 doi:10.1210/jc.2018-00229.
PMID: 29562364 - 19
Testosterone Therapy in Adolescent Boys: The Need for a Structured Approach.
Stancampiano MR, Lucas-Herald AK, Russo G, et al.
Hormone research in paediatrics 2019; (92(4)):215-228 doi:10.1159/000504670.
PMID: 31851967 - 20
NR5A1 Gene Variants: Variable Phenotypes, New Variants, Different Outcomes.
Faienza MF, Chiarito M, Baldinotti F, et al.
Sexual development : genetics, molecular biology, evolution, endocrinology, embryology, and pathology of sex determination and differentiation 2019; (13(5-6)):258-263 doi:10.1159/000507411.
PMID: 32369823 - 21
46, XY under-virilization and NR5A1 variants: Monocentric Indian experience and systematic review.
Kumar S, Pandit R, Sarathi V, et al.
Annales d'endocrinologie 2025; (86(4)):101731 doi:10.1016/j.ando.2025.101731.
PMID: 40280302 - 22
Breast development and satisfaction in women with disorders/differences of sex development.
van de Grift TC, Kreukels BPC,
Human reproduction (Oxford, England) 2019; (34(12)):2410-2417 doi:10.1093/humrep/dez230.
PMID: 31774116
This page explains hormone replacement therapy for puberty in 46,XY DSD for informational purposes only and does not constitute medical advice. A pediatric endocrinologist and multidisciplinary DSD team should tailor decisions to your child.
Get notified when new evidence is published on 46,XY difference of sex development.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.